ImageneBio, Inc. — Director's Dealing 2022

Jan 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2022-01-18

Reporting Person: Tessier Maude (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-18	Common Stock	M	38915	$2.94	Acquired	67707	Direct
2022-01-18	Common Stock	M	24606	$4.15	Acquired	92313	Direct
2022-01-18	Common Stock	M	8265	$4.51	Acquired	100578	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-18	Stock Option (Right to Buy)	$2.94	M	38915	Disposed	2028-08-08	Common Stock (38915)	Direct
2022-01-18	Stock Option (Right to Buy)	$4.15	M	24606	Disposed	2029-03-19	Common Stock (24606)	Direct
2022-01-18	Stock Option (Right to Buy)	$4.51	M	8265	Disposed	2029-12-05	Common Stock (8265)	Direct

Footnotes

F1: 25% of this option vested and became exercisable on July 16, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.

F2: 25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.

F3: 25% of this option vested and became exercisable on December 6, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.